The company is working with Vertex Pharmaceuticals to co-develop CTX001, an experimental gene therapy that has provided promising results for ...
https://www.google.com/url?rct=j&sa=t&url=https://www.forbes.com/sites/greatspeculations/2021/10/19/gene-editing-stocks-lag-on-clinical-setbacks-rising-yields-time-to-buy/&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNH4QMBVSZejbYQvP5kWiJrDn8hRxg
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.